Clinical Burden of Chronic Obstructive Pulmonary Disease in Patients with Suboptimal Peak Inspiratory Flow

被引:0
作者
Ohar, Jill A. [1 ]
Mahler, Donald A. [2 ,3 ]
Davis, Gabrielle N. [4 ]
Lombardi, David A. [4 ]
Moran, Edmund J. [4 ]
Crater, Glenn D. [4 ]
机构
[1] Wake Forest Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC USA
[2] Geisel Sch Med Dartmouth, Hanover, NH USA
[3] Valley Reg Hosp, Claremont, NH USA
[4] Theravance Biopharm US Inc, South San Francisco, CA 94080 USA
关键词
DRY POWDER; COPD; DYSPNEA; PREVALENCE; RATES; RESISTANCE; DISCHARGE; INHALERS;
D O I
10.1155/2024/8034923
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction. Many patients with chronic obstructive pulmonary disease (COPD) may derive inadequate benefit from dry powder inhalers (DPIs) because of suboptimal peak inspiratory flow (sPIF). Objectives. To assess the clinical burden of COPD by characterizing the clinical characteristics of participants with sPIF against medium-low resistance DPIs versus those with optimal PIF (oPIF) from two phase 3 clinical trials. Methods. Baseline data were collected from two randomized, controlled, phase 3 trials (NCT03095456; NCT02518139) in participants with moderate-to-severe COPD. oPIF (60 L/min) against the medium-low resistance DPIs was used as the threshold for defining the PIF subgroups (<60 L/min (sPIF) vs >= 60 L/min (oPIF)). Results. Most participants included in this analysis were White (92%) and male (63%); the mean (range) age was 65 (43-87) years. Participants with sPIF had significantly greater dyspnea than those with oPIF as measured using the modified Medical Research Council scoring (mean (95% CI): 2.1 (2.0-2.2) vs 1.6 (1.4-1.7); P < 0.001 ) and baseline dyspnea index (mean (95% CI): 5.1 (4.9-5.4) vs 6.1 (5.8-6.3); P < 0.001 ). Based on COPD Assessment Test scores, participants with sPIF had a higher COPD symptom burden than those with oPIF (mean (95% CI): 21.5 (19.7-23.3) vs 19.5 (18.6-20.4); P = 0.0 5). Conclusion. In these trials, participants with COPD who had sPIF against the medium-low resistance DPIs had more dyspnea and worse health status than those with oPIF. These results demonstrate that sPIF is associated with a higher clinical burden as measured by patient-reported outcomes.
引用
收藏
页数:8
相关论文
共 43 条
  • [1] Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?
    Al-Showair, Raid A. M.
    Tarsin, Walid Y.
    Assi, Khaled H.
    Pearson, Stantey B.
    Chrystyn, Henry
    [J]. RESPIRATORY MEDICINE, 2007, 101 (11) : 2395 - 2401
  • [2] Predictors of 30-and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study
    Alqahtani, Jaber S.
    Aldabayan, Yousef S.
    Aldhahir, Abdulelah M.
    Al Rajeh, Ahmad
    Mandal, Swapna
    Hurst, John R.
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 2769 - 2781
  • [3] [Anonymous], GLOBAL STRATEGY DIAG
  • [4] Atkins Paul J, 2005, Respir Care, V50, P1304
  • [5] Peak Inspiratory Flows Defining Repeatability Limits and a Predictive Equation for Different Inhalers
    Barnes, Chris N.
    Mahler, Donald A.
    Ohar, Jill A.
    Lombardi, David A.
    Crater, Glenn D.
    [J]. CHEST, 2020, 158 (04) : 1413 - 1419
  • [6] Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
    Donohue, James F.
    Kerwin, Edward
    Sethi, Sanjay
    Haumann, Brett
    Pendyala, Srikanth
    Dean, Lorna
    Barnes, Chris N.
    Moran, Edmund J.
    Crater, Glenn
    [J]. RESPIRATORY RESEARCH, 2019, 20 (01) : 241
  • [7] Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease
    Donohue, James F.
    Kerwin, Edward
    Sethi, Sanjay
    Haumann, Brett
    Pendyala, Srikanth
    Dean, Lorna
    Barnes, Chris N.
    Moran, Edmund J.
    Crater, Glenn
    [J]. RESPIRATORY MEDICINE, 2019, 153 : 38 - 43
  • [8] Spirometry Measurement of Peak Inspiratory Flow Identifies Suboptimal Use of Dry Powder Inhalers in Ambulatory Patients with COPD
    Duarte, Alexander G.
    Tung, Leon
    Zhang, Wei
    Hsu, En Shuo
    Kuo, Yong-Fang
    Sharma, Gulshan
    [J]. CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2019, 6 (03): : 246 - 255
  • [9] RELIABILITY AND VALIDITY OF DYSPNEA MEASURES IN PATIENTS WITH OBSTRUCTIVE LUNG-DISEASE
    EAKIN, EG
    SASSIDAMBRON, DE
    RIES, AL
    KAPLAN, RM
    [J]. INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 1995, 2 (02) : 118 - 134
  • [10] Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD
    Ghosh, Sohini
    Pleasants, Roy A.
    Ohar, Jill A.
    Donohue, James F.
    Drummond, M. Bradley
    [J]. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 585 - 595